Participated · Seed · Mar 2025

RegCell has developed a proprietary epigenetic reprogramming platform to generate stable, antigen-specific regulatory T cells (Tregs) intended to restore immune tolerance in autoimmune diseases and transplantation. The platform emphasizes epigenetic (non‑genetic) reprogramming to simplify manufacturing, enhance safety, and enable scalable production versus genetic modification approaches. RegCell plans to initiate a first-in-human clinical trial in 2025 for an antigen-specific autoimmune indication. Financially, the company closed an oversubscribed $8.5M seed financing and was awarded up to $37.3M (¥5.6 billion) in non-dilutive funding from Japan’s AMED to support IND-enabling studies, GMP optimization, and clinical proof-of-concept in the U.S. The company completed a strategic transition to a U.S.-based corporation with newly established U.S. headquarters in Emeryville, Calif., while continuing core scientific operations in Japan. RegCell is led by CEO Dr. Michael McCullar and was founded on discoveries by Professor Shimon Sakaguchi.

Led · Equity · May 2024

NSG BioLabs operates fully equipped, certified BSL-2 laboratory and office infrastructure offering equipment, efficient operations, capital efficiency, and access to expert teams and global networks. Its primary product is co-working lab and office space across 35,000 sq ft in Biopolis, Singapore, supporting R&D for health, biomedical, agrifood, and industrial biotechnology companies. The company provides services and benefits to resident teams working in areas such as precision medicine, nucleic acids, AI-enabled drug discovery, and synthetic biology. Since 2019 it has supported over 40 resident companies, whose startups have collectively raised nearly US$400M and achieved notable business milestones. NSG BioLabs is led by CEO and Founder Daphne Teo and markets itself as a capital-efficient operational platform for early-stage life sciences innovators. The company plans to use new financing to expand its facilities, augment infrastructure, and enhance value‑add services and networking opportunities for residents.

Led · Series A · Jan 2024

GDMC is an advanced therapeutic drug manufacturer that focuses on gene, tissue and cell biologics. The company emphasizes a “collaborative approach” and applies synthetic biology techniques to improve gene drug design and development. GDMC offers a “drug manufacturing organization partnership” model providing clients, including startups, with drug design, production, quality assurance, and regulatory support needed to reach market. It is developing advanced therapeutic modalities such as custom messenger RNA, plasmid DNA, and lentiviral vectors. GDMC recently closed a $21 million Series A financing. Investors in the round included Celadon Partners, Seeds Capital, NSG Ventures, and WI Harper Group.